The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (interstitial lung disease/ILD)
Publications
Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature.
Journal of chemotherapy (Florence, Italy) 2017 Apr;29;113-117 — 2017 Apr — 113-117
Delayed Paclitaxel-trastuzumab-induced interstitial pneumonitis in breast cancer.
Case reports in oncology 2011 Apr 02;4;186-91 — 2011 Apr 02 — 186-91
Paclitaxel-induced hypersensitivity pneumonitis: radiographic and CT findings.
AJR. American journal of roentgenology 2001 Mar;176;718-20 — 2001 Mar — 718-20
Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy.
Oncology 1998 Jul-Aug;55;340-4 — 1998 Jul-Aug — 340-4
Pulmonary infiltrates following administration of paclitaxel.
Chest 1996 Jul;110;289-92 — 1996 Jul — 289-92
Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996 Apr;14;1071-6 — 1996 Apr — 1071-6
Pneumonitis related to treatment with paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995 Feb;13;534-5 — 1995 Feb — 534-5